Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ISCO > SEC Filings for ISCO > Form 8-K on 15-Apr-2013All Recent SEC Filings

Show all filings for INTERNATIONAL STEM CELL CORP | Request a Trial to NEW EDGAR Online Pro

Form 8-K for INTERNATIONAL STEM CELL CORP


15-Apr-2013

Change in Directors or Principal Officers, Amendments to Articles of


ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATION ARRANGEMENTS OF CERTAIN OFFICERS

On April 9, 2013 Ms. Linh Nguyen notified the Board of Directors of International Stem Cell Corporation, a Delaware corporation, (the "Company") of her resignation as the Company's Chief Financial Officer. Her resignation will be effective April 15, 2013 but she has agreed to assist with the transition of her responsibilities following her departure. Ms. Nguyen is pursuing a career opportunity in the software industry and has indicated that her resignation did not result from any disagreement with the Company's operations, policies or practices.

The Company has appointed Mr. Jay Novak, age 47, who is currently serving as the Company's Director of Finance, as the interim Chief Financial Officer, effective April 16, 2013. Mr. Novak has over 18 years of experience in finance and accounting. He joined the Company in July 2011 and has been serving as Director of Finance since May 2012. Prior to joining the Company, Mr. Novak served as Financial Reporting Manager at Volcano Corporation, a medical device company, from April 2010 to June 2011, as a financial consultant from September 2009 until March 2010, and as Associate Director of Finance at Nanogen, Inc. from April 2007 until August 2009. He previously served as Associate Director of Finance at Elan Pharmaceuticals and as Assistant Director of Finance at Isis Pharmaceuticals. He is a certified public accountant, having begun his career with Deloitte & Touche, LLP. He received a B.S. in Accountancy from California State University, Long Beach, and an MBA from University of California, Irvine.



ITEM 5.03 AMENDMENT OF ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR

As a result of conversion in January 2013 by the holders of all shares of Series C Preferred Stock to common stock, there were no longer any shares of Series C Preferred Stock outstanding. On April 10, 2013, the Company filed a Certificate of Elimination for the Series C Preferred Stock. The Certificate of Elimination amended the provisions of the Certificate of Incorporation of the Company to eliminate the powers, designations, preferences, privileges and other rights of the Series C Preferred Stock.



ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d.) Exhibits

3.1 Certificate of Elimination for Series C Preferred Stock


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

International Stem Cell Corporation

By: /s/ Andrey Semechkin
Andrey Semechkin
Co-Chairman and Chief Executive Officer

Dated: April 15, 2013

  Add ISCO to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ISCO - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.